Hua Medicine (Shanghai) Ltd. (OTCMKTS:HUMDF) Short Interest Update

Hua Medicine (Shanghai) Ltd. (OTCMKTS:HUMDF) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 400 shares, a decline of 99.8% from the September 30th total of 175,900 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ? days.

Hua Medicine (Shanghai) Price Performance

HUMDF opened at C$0.15 on Friday. Hua Medicine has a 52 week low of C$0.15 and a 52 week high of C$0.15. The business’s 50 day moving average is C$0.18 and its two-hundred day moving average is C$0.20.

Hua Medicine (Shanghai) Company Profile

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D.